When Hans Met Sally: Our FcRn Antibody Development

When Co-founder Hans de Haard heard about Prof. Sally Ward’s immunology research at a conference in San Diego, neither realized just how far it would all lead. Learn more about Prof. Ward’s work in FcRn science and the collaboration that ultimately brought about the development of efgartigimod, a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). 

Interested in Learning More?

Get argenx news and updates right to your inbox


Download assets
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at argenx.
Follow us
Get the latest news and info via our social media channels.